Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$1.70
-2.3%
$1.85
$1.21
$3.81
$41.99M0.68261,100 shs12,034 shs
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$3.19
$3.21
$1.50
$3.87
$23.38M0.836,795 shs1 shs
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
$0.98
$0.98
$0.42
$1.25
$11.17M0.9811,250 shsN/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
$0.22
+2.4%
$0.30
$0.21
$0.71
$41.33M0.8313,089 shs500 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
0.00%+8.75%-10.77%-1.14%+10.13%
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
0.00%-0.31%-13.55%+63.59%-30.04%
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
-3.93%-11.14%-27.26%-35.54%-64.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
0.4273 of 5 stars
1.00.00.00.00.02.51.3
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
2.00
Hold$1.752.94% Upside
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
0.00
N/AN/AN/A
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
0.00
N/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
$25.07M1.67N/AN/A$4.29 per share0.40
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$257.55M0.16$7.98 per share0.40N/A
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
$54.98M0.20$0.09 per share11.09($0.80) per share-1.22
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
$9.14M4.52N/AN/A($0.01) per share-22.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%11/4/2025 (Estimated)
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$35.64MN/A0.00N/AN/AN/AN/AN/A
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
-$25.70M-$0.12N/AN/A20.88%-1,996.22%14.25%N/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
-$21.12M-$0.03N/AN/A-115.14%N/A-60.81%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/AN/AN/AN/AN/A
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
N/AN/AN/AN/AN/A
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
N/AN/AN/AN/AN/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
N/A
4.89
4.54
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
N/AN/AN/A
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
9.97
2.11
1.77
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
N/A
0.60
0.50

Institutional Ownership

CompanyInstitutional Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
52.08%
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
85.36%
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
N/A
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
0.03%

Insider Ownership

CompanyInsider Ownership
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
37.30%
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
28.90%
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
7.00%
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
47.68%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aadi Bioscience, Inc. stock logo
AADI
Aadi Bioscience
4024.70 million15.49 millionOptionable
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
10012.99 million9.23 millionNo Data
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
10011.40 million10.60 millionNot Optionable
PyroGenesis Canada Inc. stock logo
PYRGF
PyroGenesis Canada
90187.53 million96.34 millionNo Data

Recent News About These Companies

PyroGenesis Announces Second Quarter 2025 Results
PyroGenesis Announces Extension to Term of Warrants
PyroGenesis Announces First Quarter 2025 Results
PyroGenesis Provides Update on Fumed Silica Project

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aadi Bioscience stock logo

Aadi Bioscience NASDAQ:AADI

$1.70 -0.04 (-2.30%)
As of 08/25/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Eagle Pharmaceuticals stock logo

Eagle Pharmaceuticals NASDAQ:EGRX

$3.19 0.00 (0.00%)
As of 08/25/2025

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Nuvo Pharmaceuticals stock logo

Nuvo Pharmaceuticals OTCMKTS:MRVFF

$0.98 0.00 (0.00%)
As of 03/16/2023

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.

PyroGenesis Canada stock logo

PyroGenesis Canada NASDAQ:PYRGF

$0.22 +0.01 (+2.37%)
As of 03:45 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.